Bussiness5 months ago
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
RSV causes thousands of hospitalizations and deaths among seniors each year, according to data from the Centers for Disease Control and Prevention. But the virus can...